Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 in Healthy Volunteers and Adult Subjects With Bronchiectasis
NCT06166056Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Nov 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CHF-6333 in bronchiectasis, sponsored by Chiesi Farmaceutici S.p.A.. Started Nov 2023; status: completed.
02
Drugs
CHF-6333
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT06166056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06166056.